Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 2/20 | 0.43 |
| ▸ | CCR5 | P51681 | 11/20 | 0.42 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL1936089 | 0.94 | CCR5 (0.39) | PGRCCR5TP53OPRM1ACHE | |
| SCHEMBL2395603 | 0.91 | CCR5 (0.41) | PGRCCR5OPRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL2396854 | 0.89 | OPRM1 (0.41) | PGRCCR5OPRM1CHRM3 | |
| SCHEMBL3364749 | 0.89 | ACHE (0.43) | PGRCCR5TP53OPRM1ACHE | |
| SCHEMBL2394314 | 0.85 | SLC6A4 (0.46) | TP53CHRM3 | |
| Fumaric Acid SCHEMBL1936521 | 0.83 | ACHE (0.41) | PGRCCR5TP53OPRM1ACHE | |
| SCHEMBL2397352 | 0.83 | OPRK1 (0.42) | CCR5TP53OPRM1CHRM3 | |
| SCHEMBL2395364 | 0.83 | CCR5 (0.46) | CCR5OPRM1 | |
| SCHEMBL3038014 | 0.81 | OPRD1 (0.43) | CCR5OPRM1ACHECHRM3 | |
| SCHEMBL1934810 | 0.81 | PGR (0.39) | PGRCCR5OPRM1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212997-A1 | PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-09-01 | — | — | US | claimed |
| US-20110212997-A1 | PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2011-09-01 | — | — | US | disclosed |
| WO-2010023197-A2 | NOVEL PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 2010-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212997-A1 | PIPERIDINE-4-ACETAMIDE DERIVATIVES AND THEIR USE AS MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC18A3 | PGR 2155/4885CCR5 2539/4885TP53 4874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.